Peregrine fiscal Q4 top line down 5%; EPS down 140%; shares down 13% after hours

|About: Peregrine Pharmaceutic... (PPHM)|By:, SA News Editor

Peregrine Pharmaceuticals (NASDAQ:PPHM) fiscal Q4 results ($M): Contract manufacturing revenue: 17.9 (-4.8%); Net Loss: (6.7) (+49.6%); Loss/share: (0.16) (-140.0%).

Four new customers signed, expected to contribute to to revenues in fiscal 2018.

Three process validation studies completed. Revenue upside when customers build inventory and commence commercial launch.

Three clinical trials with NCCN proceeding as planned.

2018 Guidance: Manufacturing revenue:  $50M - 55M.

Shares are down 13% after hours on increased volume.